What type of study is this?

This is a Literature Review study.

What question did this study set out to answer?

This research evaluates the impact of Erythropoietin Stimulating Agents on outcomes in sickle cell disease patients using real-world data.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Real-world data analysis shows Erythropoietin use affects mortality and sickle cell crisis in SCD patients, indicating risks remain.

This research evaluates the impact of Erythropoietin Stimulating Agents on outcomes in sickle cell disease patients using real-world data.
Utilized Trinetx, a global electronic medical records dataset to isolate SCD patients over 18 years old.
Divided patients into cohorts based on receipt of ESAs, specifically EPO, Epoietin alfa, and Darbepoetin alfa.
Employed Propensity Score matching to control for confounding factors.
Evaluated outcomes including all-cause mortality, sickle cell crisis, ischemic stroke, and cardiac ischemia.
Identified 19,143 SCD patients, with 9.14% receiving EPO.
Higher all-cause mortality in the EPO group (31.94%) compared to non-EPO (8.94%).
Sickle cell crisis incidence was lower in EPO recipients (14.86% vs 36.34%).
Increased risks of ischemic stroke (11.56%), cardiac ischemia (17.91%), and arterio-venous thrombosis in EPO group.

Desai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark